Patent ID: 6159982
Filing Date: 2000-12-12
Classification: A61P,C07D

Abstract:
A compound selected from the group consisting of:N.sup.4 -cyclopropyl-N.sup.2 -methyl-N.sup.2 -[1-(phenylmethyl)-4-piperidinyl]-2,4-pyrimidinediamine;N.sup.2 -[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N.sup.4 -ethyl-N.sup.2 -methyl-2,4-pyrimidinediamine;N.sup.2 -[1-(1,3-benzodioxol-5-ylmethyl)-4-piperidinyl]-N.sup.4 -cyclopropyl-N.sup.2 -methyl-2,4-pyrimidinediamine;N.sup.2 -[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-N.sup.2,N.sup.4,N.sup.4 -trimethyl-2,4-pyrimidinediamine;N.sup.2 -[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-N.sup.2,N.sup.4,N.sup.4 -trimethyl-2,4-pyrimidinediamine;N.sup.2,N.sup.4,N.sup.4 -trimethyl-N.sup.2 -[1-[[4-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-2,4-pyrimidinediami ne;N.sup.2,N.sup.4,N.sup.4 -trimethyl-N.sup.2 -[1-[(4-methylphenyl)methyl]-4-piperidinyl]-2,4-pyrimidinediamine; andN.sup.2,N.sup.4,N.sup.4 -trimethyl-N.sup.2 -[1-[(3-methylphenyl)methyl]-4-piperidinyl]-2,4-pyrimidinediamine; a stereochemically isomeric form or a pharmaceutically acceptable addition salt thereof.